Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO 2019 Notebook: Merck; RMAT; Out-Licensing Deals

Executive Summary

News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day Zerbaxa picks up a new indication; US FDA regenerative medicine advanced therapy designations now outnumber breakthrough designations for cell/gene therapies; BIO survey finds out-licensing cash for emerging firms more than doubled in 2018.

Advertisement

Related Content

Antibiotic Incentives: Advocates Sounding The Alarm For DISARM
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
BIO 2019 Notebook: Merck On Finding The Right Balance, Sandoz On The Next Wave Of Biosimilars, NORD On Patient Engagement
BIO 2019 Notebook: Merck On Finding The Right Balance, NORD On Patient Engagement, Sandoz On The Next Wave Of Biosimilars
BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A
Merck And The 'Strange Business' Of Antibiotics
RMAT Designation Requests May Rise Or Fall On Manufacturing Changes, Clinical Data Breadth

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel